Follow
Anniina Färkkilä
Anniina Färkkilä
University of Helsinki and Helsinki University Hospital
Verified email at hus.fi - Homepage
Title
Cited by
Cited by
Year
Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma
PA Konstantinopoulos, S Waggoner, GA Vidal, M Mita, JW Moroney, ...
JAMA oncology 5 (8), 1141-1149, 2019
4712019
The Fanconi anemia pathway in cancer
J Niraj, A Färkkilä, AD D'Andrea
Annual review of cancer biology 3 (1), 457-478, 2019
3802019
Vascular endothelial growth factor-C accelerates diabetic wound healing
A Saaristo, T Tammela, A Fārkkilā, M Kärkkäinen, E Suominen, ...
The American journal of pathology 169 (3), 1080-1087, 2006
3062006
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors
J Zhou, C Gelot, C Pantelidou, A Li, H Yücel, RE Davis, A Färkkilä, ...
Nature cancer 2 (6), 598-610, 2021
2742021
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
A Färkkilä, DC Gulhan, J Casado, CA Jacobson, H Nguyen, ...
Nature communications 11 (1), 1459, 2020
2402020
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial
PA Konstantinopoulos, SC Cheng, AEW Hendrickson, RT Penson, ...
The Lancet Oncology 21 (7), 957-968, 2020
1902020
The CHK1 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and sensitizes to PARP inhibition
K Parmar, BS Kochupurakkal, JB Lazaro, ZC Wang, S Palakurthi, ...
Clinical Cancer Research 25 (20), 6127-6140, 2019
1292019
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
J Duraiswamy, R Turrini, A Minasyan, D Barras, I Crespo, AJ Grimm, ...
Cancer cell 39 (12), 1623-1642. e20, 2021
1202021
A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients
M Tumiati, S Hietanen, J Hynninen, E Pietilä, A Färkkilä, K Kaipio, ...
Clinical Cancer Research 24 (18), 4482-4493, 2018
1112018
Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary
A Färkkilä, UM Haltia, J Tapper, MK McConechy, DG Huntsman, ...
Annals of Medicine 49 (5), 435-447, 2017
1052017
Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy
S Iyer, S Zhang, S Yucel, H Horn, SG Smith, F Reinhardt, E Hoefsmit, ...
Cancer Discovery 11 (2), 384-407, 2021
952021
Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience
S Bryk, A Färkkilä, R Bützow, A Leminen, M Heikinheimo, M Anttonen, ...
International Journal of Gynecologic Cancer 25 (1), 2015
772015
Anti-Müllerian hormone inhibits growth of AMH type II receptor-positive human ovarian granulosa cell tumor cells by activating apoptosis
M Anttonen, A Färkkilä, H Tauriala, M Kauppinen, DT MacLaughlin, ...
Laboratory investigation 91 (11), 1605-1614, 2011
772011
Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype
MK McConechy, A Färkkilä, HM Horlings, A Talhouk, L Unkila-Kallio, ...
Journal of the National Cancer Institute 108 (11), djw134, 2016
732016
FOXL2, GATA4, and SMAD3 co-operatively modulate gene expression, cell viability and apoptosis in ovarian granulosa cell tumor cells
M Anttonen, M Pihlajoki, N Andersson, A Georges, D L'hôte, S Vattulainen, ...
PLoS One 9 (1), e85545, 2014
692014
TERT promoter mutation in adult granulosa cell tumor of the ovary
JA Pilsworth, DR Cochrane, Z Xia, G Aubert, AEM Färkkilä, HM Horlings, ...
Modern Pathology 31 (7), 1107-1115, 2018
682018
The clinical utility of serum anti‐M üllerian hormone in the follow‐up of ovarian adult‐type granulosa cell tumors—A comparative study with inhibin B
A Färkkilä, S Koskela, S Bryk, H Alfthan, R Bützow, A Leminen, U Puistola, ...
International Journal of Cancer 137 (7), 1661-1671, 2015
662015
Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
IM Launonen, N Lyytikäinen, J Casado, EA Anttila, A Szabó, UM Haltia, ...
Nature communications 13 (1), 835, 2022
622022
Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 are highly expressed in ovarian granulosa cell tumors
A Färkkilä, M Anttonen, J Pociuviene, A Leminen, R Butzow, ...
European journal of endocrinology 164 (1), 115-122, 2011
612011
Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors
S Bryk, A Färkkilä, R Bützow, A Leminen, J Tapper, M Heikinheimo, ...
Gynecologic Oncology 143 (3), 571-577, 2016
492016
The system can't perform the operation now. Try again later.
Articles 1–20